FINHUB Insights

ABT · Q3 FY25 · Jul 1 – Sep 30, 2025

Abbott Laboratories Q3 FY25: where the revenue came from and where it went

Abbott Laboratories Q3 FY25: revenue $11.4B (+7% year over year). Net profit $1.6B. Largest cohort Medical Devices $5.4B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jul 1 – Sep 30, 2025
Reported
Oct 29, 2025 10-Q
Sankey diagram of Abbott Laboratories's income statement for Q3 FY25: revenue of $11.4 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$11.4B +7% year over year
Gross profit$6.3B 55% margin
Operating profit$2.1B 18% margin
Net profit$1.6B 14% margin

The numbers

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 30, 2025).
ItemValueShare of revenueYear over year
Revenue 11.4 100% +7%
Medical Devices 5.4 47% +15%
Diagnostic Products 2.3 20% −7%
Nutritional Products 2.2 19% +4%
Established Pharmaceutical… 1.5 13% +7%
Cost of revenue−5.145%
Gross profit6.355% margin+0pp
Research & development−0.87%+0pp
SG&A−327%+0pp
Other−0.44%+0pp
Operating profit2.118% margin+1pp
Tax−0.6
Net profit1.614%−1pp
Filing on EDGAR More quarters of ABT

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters